The	the	O	O	O	O
glycine	glycine	CHEMICALS	O	OTHERS	I
transporter-1	transporter-1	O	O	O	O
inhibitor	inhibitor	O	O	O	O
SSR103800	ssr103800	CHEMICALS	O	OTHERS	I
displays	displays	O	O	O	O
a	a	O	O	O	O
selective	selective	O	O	O	O
and	and	O	O	O	O
specific	specific	O	O	O	O
antipsychotic-like	antipsychotic-like	O	O	O	O
profile	profile	O	O	O	O
in	in	O	O	O	O
normal	normal	O	O	O	O
and	and	O	O	O	O
transgenic	transgenic	O	O	O	O
mice	mice	O	O	O	O
.	.	O	O	O	O

Schizophrenia	schizophrenia	O	DISEASE	OTHERS	I
has	has	O	O	O	O
been	been	O	O	O	O
initially	initially	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
dysfunction	dysfunction	O	O	O	O
in	in	O	O	O	O
dopamine	dopamine	CHEMICALS	O	OTHERS	I
neurotransmission	neurotransmission	O	O	O	O
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
observation	observation	O	O	O	O
that	that	O	O	O	O
antagonists	antagonists	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
glutamate	glutamate	CHEMICALS	O	OTHERS	I
N-methyl-D-aspartate	n-methyl-d-aspartate	O	O	O	O
(	(	O	O	O	O
NMDA	nmda	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
receptor	receptor	O	O	O	O
produce	produce	O	O	O	O
schizophrenic-like	schizophrenic-like	O	O	O	O
symptoms	symptoms	O	O	O	O
in	in	O	O	O	O
humans	humans	O	O	O	O
has	has	O	O	O	O
led	led	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
idea	idea	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
dysfunctioning	dysfunctioning	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
glutamatergic	glutamatergic	O	O	O	O
system	system	O	O	O	O
via	via	O	O	O	O
its	its	O	O	O	O
NMDA	nmda	CHEMICALS	O	OTHERS	I
receptor	receptor	O	O	O	O
.	.	O	O	O	O

As	as	O	O	O	O
a	a	O	O	O	O
result	result	O	O	O	O
,	,	O	O	O	O
there	there	O	O	O	O
is	is	O	O	O	O
a	a	O	O	O	O
growing	growing	O	O	O	O
interest	interest	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
pharmacological	pharmacological	O	O	O	O
agents	agents	O	O	O	O
with	with	O	O	O	O
potential	potential	O	O	O	O
antipsychotic	antipsychotic	O	O	O	O
properties	properties	O	O	O	O
that	that	O	O	O	O
enhance	enhance	O	O	O	O
the	the	O	O	O	O
activity	activity	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
glutamatergic	glutamatergic	O	O	O	O
system	system	O	O	O	O
via	via	O	O	O	O
a	a	O	O	O	O
modulation	modulation	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
NMDA	nmda	CHEMICALS	O	OTHERS	I
receptor	receptor	O	O	O	O
.	.	O	O	O	O

Among	among	O	O	O	O
them	them	O	O	O	O
are	are	O	O	O	O
glycine	glycine	CHEMICALS	O	OTHERS	I
transporter-1	transporter-1	O	O	O	O
(	(	O	O	O	O
GlyT1	glyt1	O	O	O	O
)	)	O	O	O	O
inhibitors	inhibitors	O	O	O	O
such	such	O	O	O	O
as	as	O	O	O	O
SSR103800	ssr103800	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
which	which	O	O	O	O
indirectly	indirectly	O	O	O	O
enhance	enhance	O	O	O	O
NMDA	nmda	CHEMICALS	O	OTHERS	I
receptor	receptor	O	O	O	O
function	function	O	O	O	O
by	by	O	O	O	O
increasing	increasing	O	O	O	O
the	the	O	O	O	O
glycine	glycine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
a	a	O	O	O	O
co-agonist	co-agonist	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
NMDA	nmda	CHEMICALS	O	OTHERS	I
receptor	receptor	O	O	O	O
)	)	O	O	O	O
levels	levels	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
synapse	synapse	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
study	study	O	O	O	O
aimed	aimed	O	O	O	O
at	at	O	O	O	O
investigating	investigating	O	O	O	O
the	the	O	O	O	O
potential	potential	O	O	O	O
antipsychotic-like	antipsychotic-like	O	O	O	O
properties	properties	O	O	O	O
of	of	O	O	O	O
SSR103800	ssr103800	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
particular	particular	O	O	O	O
focus	focus	O	O	O	O
on	on	O	O	O	O
models	models	O	O	O	O
of	of	O	O	O	O
hyperactivity	hyperactivity	O	DISEASE	OTHERS	I
,	,	O	O	O	O
involving	involving	O	O	O	O
either	either	O	O	O	O
drug	drug	O	O	O	O
challenge	challenge	O	O	O	O
(	(	O	O	O	O
ie	ie	O	O	OTHERS	I
,	,	O	O	O	O
amphetamine	amphetamine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
MK-801	mk-801	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
or	or	O	O	O	O
transgenic	transgenic	O	O	O	O
mice	mice	O	O	O	O
(	(	O	O	O	O
ie	ie	O	O	OTHERS	I
,	,	O	O	O	O
NMDA	nmda	CHEMICALS	O	OTHERS	I
Nr1(neo-/-	nr1(neo-/-	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
DAT(-/-	dat(-/-	O	O	O	O
)	)	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Results	results	O	O	O	O
showed	showed	O	O	O	O
that	that	O	O	O	O
SSR103800	ssr103800	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
10	10	O	O	O	O
-	-	O	O	O	O
30	30	O	O	O	O
mg/kg	mg/kg	O	O	O	O
p.o	p.o	O	O	O	O
.	.	O	O	O	O
)	)	O	O	O	O
blocked	blocked	O	O	O	O
hyperactivity	hyperactivity	O	DISEASE	OTHERS	I
induced	induced	O	O	O	O
by	by	O	O	O	O
the	the	O	O	O	O
non-competitive	non-competitive	O	O	O	O
NMDA	nmda	CHEMICALS	O	OTHERS	I
receptor	receptor	O	O	O	O
antagonist	antagonist	O	O	O	O
,	,	O	O	O	O
MK-801	mk-801	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
partially	partially	O	O	O	O
reversed	reversed	O	O	O	O
spontaneous	spontaneous	O	O	O	O
hyperactivity	hyperactivity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
NMDA	nmda	CHEMICALS	O	OTHERS	I
Nr1(neo-/-	nr1(neo-/-	O	O	O	O
)	)	O	O	O	O
mice	mice	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
contrast	contrast	O	O	OTHERS	I
,	,	O	O	O	O
SSR103800	ssr103800	CHEMICALS	O	OTHERS	I
failed	failed	O	O	O	O
to	to	O	O	O	O
affect	affect	O	O	O	O
hyperactivity	hyperactivity	O	DISEASE	OTHERS	I
induced	induced	O	O	O	O
by	by	O	O	O	O
amphetamine	amphetamine	CHEMICALS	O	OTHERS	I
or	or	O	O	O	O
naturally	naturally	O	O	O	O
observed	observed	O	O	O	O
in	in	O	O	O	O
dopamine	dopamine	CHEMICALS	O	OTHERS	I
transporter	transporter	O	O	O	O
(	(	O	O	O	O
DAT(-/-	dat(-/-	O	O	O	O
)	)	O	O	O	O
)	)	O	O	O	O
knockout	knockout	O	O	O	O
mice	mice	O	O	O	O
(	(	O	O	O	O
10	10	O	O	O	O
-	-	O	O	O	O
30	30	O	O	O	O
mg/kg	mg/kg	O	O	O	O
p.o	p.o	O	O	O	O
.	.	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Importantly	importantly	O	O	O	O
,	,	O	O	O	O
both	both	O	O	O	O
classical	classical	O	O	O	O
(	(	O	O	O	O
haloperidol	haloperidol	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
and	and	O	O	O	O
atypical	atypical	O	O	O	O
(	(	O	O	O	O
olanzapine	olanzapine	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
clozapine	clozapine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
aripiprazole	aripiprazole	O	O	OTHERS	I
)	)	O	O	O	O
antipsychotics	antipsychotics	CHEMICALS	O	OTHERS	I
were	were	O	O	O	O
effective	effective	O	O	O	O
in	in	O	O	O	O
all	all	O	O	O	O
these	these	O	O	O	O
models	models	O	O	O	O
of	of	O	O	O	O
hyperactivity	hyperactivity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
unlike	unlike	O	O	O	O
these	these	O	O	O	O
latter	latter	O	O	O	O
,	,	O	O	O	O
SSR103800	ssr103800	CHEMICALS	O	OTHERS	I
did	did	O	O	O	O
not	not	O	O	O	O
produce	produce	O	O	O	O
catalepsy	catalepsy	O	DISEASE	OTHERS	I
(	(	O	O	O	O
retention	retention	O	O	O	O
on	on	O	O	O	O
the	the	O	O	O	O
bar	bar	O	O	O	O
test	test	O	O	O	O
)	)	O	O	O	O
up	up	O	O	O	O
to	to	O	O	O	O
30	30	O	O	O	O
mg/kg	mg/kg	O	O	O	O
p.o	p.o	O	O	O	O
.	.	O	O	O	O

Together	together	O	O	O	O
these	these	O	O	O	O
findings	findings	O	O	O	O
show	show	O	O	O	O
that	that	O	O	O	O
the	the	O	O	O	O
GlyT1	glyt1	O	O	O	O
inhibitor	inhibitor	O	O	O	O
,	,	O	O	O	O
SSR103800	ssr103800	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
produces	produces	O	O	O	O
antipsychotic-like	antipsychotic-like	O	O	O	O
effects	effects	O	O	O	O
,	,	O	O	O	O
which	which	O	O	O	O
differ	differ	O	O	O	O
from	from	O	O	O	O
those	those	O	O	O	O
observed	observed	O	O	O	O
with	with	O	O	O	O
compounds	compounds	O	O	O	O
primarily	primarily	O	O	O	O
targeting	targeting	O	O	O	O
the	the	O	O	O	O
dopaminergic	dopaminergic	O	O	O	O
system	system	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
has	has	O	O	O	O
a	a	O	O	O	O
reduced	reduced	O	O	O	O
side-effect	side-effect	O	O	O	O
potential	potential	O	O	O	O
as	as	O	O	O	O
compared	compared	O	O	O	O
with	with	O	O	O	O
these	these	O	O	O	O
latter	latter	O	O	O	O
drugs	drugs	O	O	O	O
.	.	O	O	O	O

